肺癌是世界上最常见的恶性肿瘤之一,其中非小细胞肺癌(non-small cell lung cancer,NSCLC)约占肺癌的80%～85%。手术、化疗和放射治疗是NSCLC的主要治疗方法。随着对肿瘤发病机制及其生物学行为研究的不断深入,以特异性高、不良反应轻为特点的分子靶向治疗成为关注的焦点,如针对EGFR、K-ras和VEGF基因的靶向治疗。约70%以上的NSCLC患者不可能接受以EGFR基因突变为靶点的 Lung cancer is one of the most common malignancies in the world, with non-small cell lung cancer (NSCLC) accounting for about 80% -85% of lung cancers. Surgery, chemotherapy and radiation therapy are the main treatments for NSCLC. With the deepening of the research on the pathogenesis of tumor and its biological behavior, molecular targeted therapies characterized by high specificity and adverse reactions are the focus of attention, such as targeted therapy targeting EGFR, K-ras and VEGF genes . About 70% of NSCLC patients can not accept EGFR gene mutation as the target